{'fraction_non_alphanumeric': 0.049693072201110786, 'fraction_numerical': 0.02981584332066647, 'mean_word_length': 4.760942760942761, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 5037: Erythrocyte levels of cadmium and lead and risk of B-cell non-Hodgkin lymphoma and multiple myeloma

Heavy metals such as cadmium and lead are ubiquitous in the environment and have been classified as carcinogens by the International Agency for Research on Cancer. While research is limited, associations of heavy metals with risk of lymphoid malignancies is plausible given that other environmental factors have been associated with these cancers. To further explore associations of cadmium and lead exposure with risk of lymphoid malignancies, we conducted a nested case-control study within the Cancer Prevention Study-II (CPS-II) Nutrition cohort, a U.S. prospective cohort of men and women. Incident B-cell non-Hodgkin lymphomas (B-NHL) and multiple myelomas (MM) were identified from 32,704 CPS-II participants who were cancer-free at time of blood collection between 1998-2001. Cases included the following histologic subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), and other B-cell lymphoma. Each case was matched to two eligible controls that were selected among those who were cancer-free at the time of the case’s diagnosis. The matching factors included race, age, gender, and blood draw date. Cadmium and lead levels were measured in stored erythrocytes from the blood draw. Conditional logistic regression models were used to estimate relative risks (RR) and 95% confidence intervals (CI) for lymphoid malignancy overall and stratified by NHL subtype. The final analytic cohort consisted of 375 B-NHL or MM cases (95 DBLCL, 90 CLL/SLL, 62 FL, 76 MM, and 52 other B-cell lymphoma), and 750 matched controls. The cohort was 56% male, and an average of 69.9 years of age at the time of blood draw. There was a significant, positive association between erythrocyte levels of lead and risk of lymphoid malignancy overall (RR: 1.17, 95% CI: 1.03 - 1.33 per 1 standard deviation (SD; 17.6 µg/L) increase in lead level). This association appeared to be driven by FL (per SD of lead RR: 1.76, 95% CI: 1.21 - 2.57). No associations between lead and DLBCL, CLL/SLL, MM, or other B-cell lymphoma were observed. Results appeared similar when additionally controlling for alcohol use and smoking status. There was no association between cadmium and lymphoid malignancies overall; however, cadmium was inversely associated with risk of multiple myeloma (Q4 vs Q1 RR: 0.30, 95% CI: 0.12 - 0.75). Preliminary results from this nested case-control analysis suggests that a positive association between erythrocyte lead levels and risk of lymphoid malignancies (particularly follicular lymphoma) may exist. Reasons for an inverse association between cadmium and risk of multiple myeloma are unclear but might be due to chance. Further research is needed to fully explore and confirm these findings. Citation Format: Emily L. Deubler, Susan M. Gapstur, W. Ryan Diver, Mia M. Gaudet, James M. Hodge, Victoria L. Stevens, Marjorie L. McCullough, Laura G. Haines, Keith E. Levine, Lauren R. Teras. Erythrocyte levels of cadmium and lead and risk of B-cell non-Hodgkin lymphoma and multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5037.